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Primary Central Nervous System Lymphoma (PCNSL) is a rare neoplasm that can involve brain, eye, leptomeninges, and rarely
spinal cord. PCNSL lesions most typically enhance homogeneously on T1-weighted magnetic resonance imaging (MRI) and
appear T2-hypointense, but high variability in MRI features is commonly encountered. Neurological symptoms and MRI findings
may mimic high grade gliomas (HGGs), tumefactive demyelinating lesions (TDLs), or infectious and granulomatous diseases.
Advanced MRI techniques (MR diffusion, spectroscopy, and perfusion) and metabolic imaging, such as Fluorodeoxyglucose
Positron Emission Tomography (FDG-PET) or amino acid PET (usually employing methionine), may be useful in distinguishing
these different entities and monitoring the disease course. Moreover, emerging data suggest a role for cerebrospinal fluid (CSF)
markers in predicting prognosis and response to treatments. In this review, we will address the challenges in PCNSL diagnosis,
assessment of response to treatments, and evaluation of potential neurotoxicity related to chemotherapy and radiotherapy.
1. Introduction
Primary Central Nervous System Lymphoma (PCNSL) is
a rare extranodal non-Hodgkin lymphoma (NHL), which
can involve brain, eye leptomeninges, and rarely spinal cord
without evidence of systemic disease. PCNSL accounts for
1 to 3% of all NHL and about 3% of all primary brain
tumours [1]. Approximately 95% of PCNSLs are diffuse large
B-cell lymphomas, while the other 5% include T-cell, Burkitt,
lymphoblastic, and marginal zone lymphomas [2]. Median
age at disease presentation is 65 years, with a trend toward
an increase of incidence in the oldest population [1, 3].
Risk factors for PCNSL include congenital and acquired
immunosuppression (particularly HIV and posttransplant
conditions).
Several pathogenetic mechanisms have been related to
PCNSL, namely, mutations in specific genes (e.g., MYD88,
PIM1, ATM, and TP53) and dysregulation in JAK/STAT, NF-
kB, toll-like receptor, and B-cell receptor signaling pathways.
PCNSL frequently shows 9p.24/PD-L1/PD-2 translocations
and copy number alterations compared to other large B-cell
lymphomas. Moreover, PCNSL has a selective angiotropism:
the accumulation of tumor cells around blood vessels is
thought to be the main cause of disruption of blood-brain
barrier (BBB) [4]. From a pathological point of view, PCNSL
is a “whole-brain disease” [5, 6], an important concept for
both diagnosis and treatment.
In this review, we will discuss the challenges in the
diagnosis and monitoring of PCNSL and also focus on
baseline and long-term cognitive profile of PCSNL patients.
2. Clinical Aspects
PCNSL presentation is commonly subacute with typical
symptoms such as cognitive decline or personality changes,
confusion, focal neurological deficits, headache, and/or nau-
sea and vomiting due to intracranial hypertension. Some-
times rapid worsening of neurological status up to stupor can
be seen. Seizures are less frequent in comparison to other
brain tumors (10%-20% of patients) [7]. Leptomeningeal
involvement is detected in 15-20% of cases [8], while symp-
toms (blurred vision and decreased acuity) due to ocular
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involvement (vitreous/retina) are seen in 30% and may
precede or coexist with neurological symptoms [9].
Systemic B symptoms are unusual in patients with
PCNSL.
Corticosteroids may induce a rapid improvement in
clinical symptoms and radiographic features, and it is well
known that at least 40% of the patients show steroid-induced
responses. This point is important clinically but may be a
disadvantage leading to false negative biopsies, thus delaying
definitive diagnosis for months and even years. For this
reason, until the diagnosis is established, corticosteroids
should not be prescribed if there is a suspicion of PCNSL,
unless severe worsening of patient’s conditions occurs [4].
3. PCNSL Diagnosis: Role of Standard and
Advanced MRI
Most common locations on MRI include periventricular
white matter, basal ganglia, and corpus callosum [Figure 1],
while cerebellum, brainstem, and spinal cord are less fre-
quently involved [10]. In particular, spinal involvement is
very uncommon and is seen in 3% of patients with PCNSL.
Themost common intramedullary localization is the cervical
cord, with solitary lesions in the majority of patients [2, 10].
Due to the high cellularity, lesions are often hyperdense
on CT and hypointense on T2-weighted MRI images with
a variable amount of peritumoral edema [11, 12]. In most
cases, the lesions enhance homogeneously [Figure 2(a)], but
sometimes the enhancement is mild or with a ring pattern or
is even absent [13]. Single lesions account for 70%of cases and
multiple lesions for 30%: a multifocal presentation is more
frequent in immunocompromised patients.
The differential diagnosis is with high grade gliomas
(HGGs) and less often TDLs (tumefactive demyelinating
lesions), metastases (MTS), and infectious and granuloma-
tous diseases [14].
3.1. PCNSL versus HGG. Themost significantMRI difference
between PCNSL and HGG is the pattern of enhancement:
homogeneous in PCNSLs and heterogeneous with necrotic
areas in HGGs. Furthermore, optic tracts and basal ganglia
infiltration are more frequent in PCNSL, while cerebral cor-
tex is affected more often in HGGs; nonetheless, “superficial”
PCNSL variants mimicking HGG can be found [15, 16].
Many studies have explored diffusion-weighted imaging
(DWI) findings in PCNSL and gliomas [15, 17–24]. PCNSLs
have higher cellularity and nuclear-cytoplasm ratio than
glioblastomas (GBMs). Thus, in PCNSL, diffusion is more
restricted with lower apparent diffusion coefficient (ADC)
in comparison to GBM. GBMs have a solid portion, which
can show a restricted diffusion, but their cystic-necrotic
areas display high water molecules diffusion [15, 17–19].
Some authors have shown that the relative minimum appar-
ent diffusion coefficient (rADCmin) is the most accurate
parameter to differentiate PCNSL from GBM [22, 25, 26],
and a cut-off value of 0.722 has been suggested, with 74.5%
sensitivity and 74.1% specificity [26]. Another study [27]
demonstrated that the initial area under the curve (IAUC)
Figure 1: Contrast-enhanced axial T1-weighted MRI showing a
PCNSL located in corpus callosum.
derived from dynamic contrast-enhanced MRI (DCE) may
be a useful parameter together with ADC for differentiating
PCNSL from atypical GBM (i.e., GBMwith absent or limited
necrosis), and thus the combination of quantitative ADC
and permeability parameters from DCE MRI in tumor and
peritumoral areas could help in discriminating PCNSL versus
HGG [28].
1H-magnetic resonance spectroscopy (1H-MRS) can help
in the differential diagnosis between PCNSL and GBM.
Both tumors usually show reduced N-acetylaspartate (NAA)
peaks (neuronal damage), elevated choline to creatine ratio
(elevated membrane turnover), lipid peaks (due to release
of fatty moieties by transformed lymphocytes in PCNSL
and due to necrosis in GBM), and lactate peaks (anaerobic
metabolism). An increase in lipid resonance in the absence
of necrosis seems to be the most specific finding in PCNSL
[29–31] [Figures 2(b)-2(c)]. Nonetheless, given the difficulty
in excluding small necrotic areas in many GBMs, other peaks
have been investigated, such as glutamate (Glu) and glycine
(Gln) [32]: Aburano et al. [33] reported that PCNSL shows
higher Glu/Cr and Glu/Glu+Gln ratios than GBM.
Jiang et al. [34] investigated the usefulness of amide
proton transfer weighted studies (APTW) in the diagnosis of
PCNSL. APT is a technique that detects endogenous mobile
proteins and peptides in tissue, such as those dissolved in
cytoplasm. PCNSL has a high nuclear-cytoplasm ratio and
prominent nucleoli and a relative low concentration ofmobile
proteins. APTW imaging in PCNSL shows homogeneous
hyperintensities in enhancing areas, while HGGs have quite
heterogeneous APTW hyperintensities, more often larger
than the Gd-T1 lesions.
PCNSLs lack abundant neovascularization [35]: thus,
on dynamic susceptibility contrast-enhanced MRI (DSCE-
MRI), they show higher regional cerebral blood volume
(rCBV) than normal tissue but lower rCBV when compared
to the GBMs [25, 36, 37] [Figures 2(d)-2(e)]. Blasel et al.
[38] demonstrated in PCNSL a typical “shoulder-like” pattern
of signal intensity dynamics in most cases. Another study
[39] identified a threshold in the rCBV value (2.56), which
could be used to differentiate PCNSL from HGG with >90%
sensitivity and specificity and argued that the combination
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Figure 2: (a) Left temporoparietal PCNSL characterized by a homogeneous enhancing lesion on T1-weighted and (b) relatively low and
inhomogeneous T2 signal on T2-weighted MRI. (c) Increased lipid peak on MRI spectroscopy and (d-e) increase of the regional cerebral
blood volume (rCBV) when compared to the contralateral hemisphere.
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of rCBV and percentage of signal intensity recovery derived
from DSCE-MRI could increase the accuracy of diagnosis.
3.1.1. Take Home Message. In the daily clinical practice, in
addition to MRI morphological features, DSCE-MRI and
MRS are themost reliable tools for a differential diagnosis and
should be performed in particular in elderly patients when a
surgical approach (biopsy versus resection) is to be decided.
3.2. PCNSL versus TDL. Tumefactive demyelinating lesions
are sometimes another challenging differential diagnosis,
especially in younger patients. On MRI, TDLs are solitary
lesions, with T2-FLAIR hyperintense appearance, larger than
2 cm with mass effect and/or edema and variable enhance-
ment patterns (homogeneous or heterogeneous, nodular or
diffuse, punctate, open, or closed rings) [40]. Symptoms at
initial presentation include headache, cognitive impairment,
seizures, confusion, and impaired state of consciousness,
which are common in PCNSL patients as well. Nonethe-
less, TDL patients have a clinical and radiological response
to steroid therapy similar to that observed in PCNSL
patients.
For a noninvasive diagnosis of TDLs, advanced imaging
techniques are widely used.The typical DWI feature of TDLs
is the heterogeneity of ADC values [41]. Myelin destruction
and vasogenic edema can cause ADC increase [30, 42], but
TDLs can also show reducedADCvalues due to infiltration of
inflammatory cells, especially in the periphery of the lesions
[43]. Overall, TDLs consist of hypocellular lesions with ADC
values higher than PCNSL, which conversely shows lower,
homogeneous ADC values given the high cellularity [26,
44].
On DSCE-MRI, rCBV values are higher in PCNSL
than TDLs [44]. MRS findings can be similar in PCNSL
and TDL, consisting in decreased NAA (neuronal dam-
age in PCNSL/axonal injury in TDL), increased choline
(proliferation in PCNSL/myelin breakdown in TDL), lipid
peak (fatty moieties released by transformed lymphocytes in
PCNSL/membrane breakdown in TDL), and/or lactate peak
(anaerobic metabolism in both entities) [45–47].
PCNSL may rarely be preceded by “sentinel demyeli-
nation,” an entity characterized by histologically confirmed
demyelinating inflammatory lesions, which mimics multi-
ple sclerosis (MS) or acute disseminated encephalomyelitis
(ADEM) [48–52]. It has been hypothesized that T-cell infil-
trates, which can be found at biopsy, represent a cell-mediated
immune response against the lymphoma, thereby masking
the diagnosis of PCNSL [53, 54]. Another hypothesis is that
steroids, administrated prior to brain biopsy, disrupt B-cell
lymphoma cells, whereas activated T-cells may be relatively
protected from steroid-induced apoptosis [54]. In this regard,
a recent retrospective study examining approximately 1000
cases of PCNSL has reported that the effects of corticosteroids
given before the biopsy rendered an accurate diagnosis
difficult in up to 50% of cases [55].
Red flags suggesting PCNSL include advanced age, wors-
ening of clinical conditions despite treatment for a demyeli-
nating disease, and lesions progression on neuroimaging
studies over time. Conversely, MS onset in old patients
is often characterized by spinal cord involvement [49]. To
improve the differential diagnosis between demyelinating
diseases and PCNSL, tools such as visual evoked potentials,
spinal cord MRI, and cerebrospinal fluid (CSF) examination
for oligoclonal bands should always be performed.Moreover,
especially in younger patients, a search in the past history
for minor episodes of subacute visual or neurological deficits
with spontaneous resolution, suggestive of a first MS relapse,
should be performed.
3.2.1. Take Home Message. In the daily clinical practice, this
diagnostic problem is rare; however, when present, a com-
bination of radiological, neurophysiological, and laboratory
findings and the evaluation of their changes over time are
needed.
3.3. PCNSL versus MTS. The typical localization of metas-
tases includes the cortical gray-white matter junction of cere-
bral hemispheres, cerebellum, and basal ganglia in decreasing
order. On MRI brain MTS can be solitary (40%) or multiple
(60%), often with central necrosis, a peripheral ring of
enhancement, and extensive edema [56–58].OnDWI,metas-
tases show reduced diffusivity in the peripheral enhancing
part and increased diffusivity in the central necrotic area
and surrounding edema,while PCNSLs show a homogeneous
reduced diffusivity due to the high cellularity [59]. rCBV
is lower in PCNSL than metastases, due to lack of neovas-
cularization. MRS studies investigating differences between
PCNSL and metastases are not available.
3.3.1. Take HomeMessage. In the daily clinical practice, when
multiple lesions are evident on MRI, a differential diagnosis
between brainmetastases and PCNSL should always be taken
in mind.
3.4. PCNSL versus Infectious and Granulomatous Diseases.
In AIDS patients, a differential diagnosis between PCNSL
and Toxoplasmosis Encephalitis (TE) is not always straight-
forward, since these two entities can show similar clinical
findings and mass lesions on imaging. Clinically, patients
with TE can present either acutely or insidiously with variable
combination of headache, fever, encephalopathy, seizures,
and focal deficits. OnMRI, TE lesions are generally isointense
to hypointense on T1-weighted images with ring or nodular
enhancement, while in T2 they appear as hyperintense (dur-
ing liquefactive necrosis), hypointense (in the posttreatment
phase), or isointense, depending on the stage and composi-
tion of the abscess. They are often located in basal ganglia or
in the junction between the white and gray matter of cerebral
hemispheres and less commonly in the brainstem. Extensive
T2-hyperintense vasogenic edema is typically present. Toxo-
plasma encephalitis lesions are multifocal on MRI in 86% of
cases [60].
In DWI studies, TE lesions show higher ADC values
than PCNSL [61]. The ability of MRS to differentiate TE
from PCNSL depends on the voxel placement over necrotic
or cellular areas and on the lesion stage. Nonetheless, in
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typical cases, lipid/lactate peaks (reflecting anaerobic, necro-
tizing inflammatory process) are present without elevated
Cho/Cr ratio typical of PCNSL. Last, rCBV values are
substantially higher in PCNSL as compared to TE lesions
[62].
Neurosarcoidosis can present with multiple enhanc-
ing brain lesions mimicking PCNSL. Magnetic resonance
imaging findings are variable. About 40% of patients with
neurosarcoidosis have either leptomeningeal enhancement
or multiple white matter enhancing lesions [63]. In these
cases, differential diagnosis should be based on serum ACE
levels, CSF examination (usually with pleocytosis, increased
protein level, and oligoclonal bands), chest high-resolution
CT (HRCT), and bronchoalveolar lavage (BAL). Nonetheless,
biopsy of suspected granulomatous lesions is the gold stan-
dard for diagnosis [64].
3.4.1. Take Home Message. In the daily clinical practice, this
diagnostic problem is rare. However, patient history, CSF, and
serum analysis are fundamental to exclude the hypothesis
of infectious diseases. In particular CSF examination, ACE
levels and HRTC are needed to exclude the hypothesis of
neurosarcoidosis.
4. PCNSL Diagnosis: Role of PET
In 1992, Rosenfeld et al. reported a strong 18F-Fluorodeox-
yglucose (18F-FDG) uptake in a group of 10 patients with
PCNSL [65].These characteristics dependon the high cellular
density and increase glucose metabolism: the semiquan-
titative 18F-FDG uptake values, measured by maximum
standardize uptake value (SUVmax), are reported to be 14–22
in PCNSL, and this value is about 2.5 times higher than the
average SUV in the normal gray matter [66]. However, the
high uptake of basal ganglia, cerebral cortex, and thalamus
makes the diagnosis problematic.
18-FDG PET can play a role for diagnosis in patients who
cannot undergo brain biopsy due to surgical risks, older age,
or comorbidities. Yamaguchi et al. [67] demonstrated that
inoperable PCNSL can indirectly be diagnosed with good
accuracy on the basis of some PET-MRI criteria: extremely
high tumor FDG uptake relative to normal gray matter and
tumor reduction 1 week after corticosteroid administration
on contrast-enhanced T1-weighted MRI.
Total body 18F-FDG-PET has an important role in
PCNSL staging at diagnosis or in the follow-up, as it can
diagnose a systemic disease with higher sensitivity than
conventional imaging. Mohile et al. [68] showed that 7% of
patients with suspected PCNSL were found to have systemic
NHL by total body FDG-PET, while body CT scans and bone
marrow biopsies were negative. Moreover, total body FDG-
PET was positive in 27% of patients during restaging for
recurrent disease.
Regarding amino acid PET, methionine (MET) uptake
reflects an increase of amino acid transport and protein
synthesis and is related to cellular proliferation. In the
evaluation of brain lesions, MET has some advantages over
FDG, stemming primarily from a low uptake in the nor-
mal brain. MET is thought to be useful for delineating
tumor boundaries of PCNSL, with the area of increased
uptake being larger than the enhancing lesions on MRI
[69]. Kawase et al. [70] did not find significant differences
between T/N (tumor to normal contralateral cortex activity)
ratios on MET-PET and FDG-PET, although mean values
of SUV on MET-PET in CNS lymphomas were significantly
lower than those on FDG-PET. In this case series, 2 of
13 FDG-PET scans did not show a marked accumulation
in the tumor (small disseminated lesions in one case and
disseminated lesions overlaying the cortex in the other
case), while increased MET uptake was observed in both
patients.
Nonetheless, the experience in the use of amino acid PET
in patients with PCNSL is still limited.
Take Home Message. The typical PCNSL metabolic pattern
is an area of high homogeneous increase of 18F-FDG, more
often in subcortical regions. Frequently, this area is more vis-
ible at visual analysis due to the presence of hypometabolism
in the adjacent cortex because of compression or edema
phenomena.
These patterns are maintained in the disease recurrence
as well [Figure 3].
4.1. PCNSL versus GBM or MTS. The 18F-FDG uptake in
PCNSL is usually homogenous in contrast to the inho-
mogeneous uptake in GBMs and metastases. Kosaka et al.
[71] identified maximum standard uptake values (SUVmax)
on FDG-PET as the most important parameter for distin-
guishing lymphomas from other brain tumors. They used a
SUVmax of 15 as a cut-off for diagnosing CNS lymphoma,
and only one high grade glioma yielded a false-positive result.
Based on these findings, Makino et al. [72] demonstrated that
the accuracy of FDG-PET for differentiation of PCNSL versus
GBMs and metastases was 0.86 when the SUVmax cut-off
value was set at 12 with sensitivity of 100% and specificity of
71.4%.
Yamaguchi et al. [67] showed that FDG uptake using the
T/N ratio was more reliable than SUVmax, since SUVmax
is influenced by plasma glucose levels. The appropriate T/N
ratio cut-off point was 2.0 for differentiating PCNSL (T/N
ratio > 2) from other malignancies (GBMs and metastases)
when patients were not on corticosteroids. FDGuptake could
be influenced by cumulative doses of corticosteroid before
a PET scan, a point that should always be considered. A
recent meta-analysis [73] on 18F-FDG PET and PET/CT
in PCNSL, based on 8 retrospectives studies (129 patients),
revealed pooled sensitivity and specificity of 18F-FDG-PET
and PET/CT in the diagnosis of PCNSL of 0.88 and 0.86,
respectively.
Okada et al. [69] suggested higher FDG-PET SUVmax
and higher ΔSUVmax (ratio of SUVmax in the late and early
phase) on MET-PET for PCNSL compared with GBM.
Take Home Message. SUVmax is influenced by different
factors, in particular the sensitivity of the PET scanner.
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Figure 3: 18F-FDG brain imaging in a 66-year-old woman with PCNSL. Axial CT (a), PET (b), and PET/CT fusion image (c) showing the
FDG-avid lesion involving the left frontal lobe (SUVmax 42). (d) Maximum imaging projection (MIP), axial CT (e), and PET/CT fusion
image (f) showing another lesion on the left cerebellar hemisphere.
Therefore, particular attention must be paid when the values
of this parameter are imported from literature into own
clinical routine.
4.2. PCNSL versus TDL. Schiepers et al. [74] reported that
active lesions in acute multiple sclerosis are hypermetabolic,
while chronic lesions are hypometabolic: thus, glucose uptake
could be a marker of the temporal stage of a plaque.
Takenaka et al. [75] studied 6 cases of TDLs and found a
mean FDG T/N ratio similar to the glucose metabolism of
normal cortex and lower than those of GBMs. The same
authors described a lower MET uptake in TDL than in glial
malignancies. Padma et al. [76] reported low glucose uptake
and prominent methionine uptake in a case of TDL: the
authors hypothesized that MET uptake in the lesion was
related to inflammation and blood-brain barrier disruption.
Maffione et al. [77] described moderate focal glucose uptake
in two TDLs (SUVmax 6.9 in both cases). Overall, studies
comparing 18F-FDG PET and MET-PET findings in PCNSL
and TDLs are lacking. Patients with demyelinating diseases
can show diffuse cortical hypometabolism due to chronic
white matter damage [78, 79], especially in patients with
subacute/chronic neurological impairment and small white
matter lesions. However, cortical hypometabolism does not
exclude a diagnosis of lymphoma, as it can be an expression of
a cortical disconnection due to white matter lesions (tumoral
or not). The use of MET-PET could more precisely indicate
the presence of a tumoral lesion [80].
TakeHomeMessage. In case of negative or doubtful results at 1
hour 18F-FDG postinjection images, it is advisable to repeat a
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delayed PET acquisition at 4 hours after injection. In some
cases, this procedure allows an improvement in the visual
analysis.
4.3. PCNSL versus Infectious and Granulomatous Diseases. In
patients with acquired immunodeficiency syndrome (AIDS),
18F-FDG uptake can be used to distinguish between cere-
bral PCNSL (highly metabolic lesions) and toxoplasmosis
(hypometabolic lesions) [81].
Neurosarcoidosis can be hypermetabolic on brain 18F-
FDG-PET [82]. In suspected neurosarcoidosis, whole-body
FDG-PET can help in localizing granulomatous lesions,
which can be a target for biopsy [82]. MET-PET yields
similar results. Kawai et al. [66] described a series of
nontumoral lesions with moderate MET uptake, including
brain abscesses. Ng et al. [51] demonstrated MET uptake
and high FDG uptake in multiple brain lesions due to
neurosarcoidosis.These results are not surprising, sinceMET
uptake can be increased as a result of increased density of
inflammatory cells and disruption of the blood-brain barrier
(BBB).
Take Home Message. 18-FDG-PET should be performed,
together with MRI spectroscopy and perfusion MRI, when
suspecting a PCNSL prior to steroid treatment and biopsy.
To date, the major limitation of 18F-FDG-PET is the diffi-
culty to diagnose PCNSLs with atypical radiological findings
(disseminated or nonenhancing lesions) [Figure 4]. Further
studies are needed to determine the diagnostic value of MET
uptake and the usefulness of combining MET with FDG-
PET.Nonetheless, the ability ofMET-PET to detect PCNSL in
disseminated or cortical lesions suggest a role in the diagnosis
of suspected PCNSL with atypical findings.
5. PCNSL Diagnosis: Role of CSF
A recent review on the accuracy of flow cytometry (FCM)
and cytomorphology (CM) in the diagnosis of meningeal
involvement from lymphoid neoplasms [83], based on 27
studies, demonstrated a great heterogeneity: positive results
with both FCM and CM range from 0.3% to 42.9% among
studies. Samples with positive FCM but negative CM are
reported by 89% of the studies, while samples with positive
CM and negative FCM are found in 48%. In a study by
Schroers et al. [84] regarding a cohort of PCNSL patients,
23.3%were positive for CSF lymphoma cells with flow cytom-
etry in contrast to 13.3% patients with positive cytopathology.
It must be noted that CSF cells are particularly fragile and
must be analyzed in the hours following the examination or
be put in a stabilizing suspension. Overall, one can suggest
employing flow cytometry along with conventional cytology
to increase the number of positive CSF cells. Anothermethod
to detect mature B lymphoid cells is PCR testing for IgH gene
rearrangements, which does not require intact cells [85].
Studies regarding the diagnostic role of different CSF
markers (interleukins, chemokines, and receptors) and miR-
NAs are ongoing. Interleukin-10 (IL-10) and its receptors
are expressed in PCNSL and act as a growth factor for B
lymphocytes, while IL-6 is related to lymphoid cells growth
and immunity regulation. Sasayama et al. [86] demonstrated
that CSF IL-10 and IL-6 levels are significantly higher in
PCNSLs than in other brain tumors: at an IL-10 cut-off level
of 9.5 pg/mL, the sensitivity and specificity were 71.0% and
100%, respectively. Nguyen-Them et al. [87] reported that
IL-10 CSF concentration can distinguish PCNSL from other
neurologic diseaseswith sensitivity of 88.6% and specificity of
88.9%with a cut-off of 4 pg/ml, while Song et al. [88] reported
diagnostic sensitivity and specificity of 95.5% and 96.1%,
respectively, when IL-10 levels cut-off was set at 8.2 pg/ml.
Osteopontin (OPN) is another proinflammatory cytokine
involved in immune cell activation and B-cell migration
and proliferation. Strehlow et al. [89] demonstrated that
CSF OPN levels in PCNSL patients are significantly higher
(> 620 ng/mL) than those in patients with inflammatory
CNS disease and GBM or in healthy controls. Similarly,
Viaccoz et al. [90] reported that CSF neopterin (a marker of
neuroinflammation) levels are significantly higher in patients
with PCNSL than in those with other brain tumors, pseu-
dotumoral inflammatory brain lesions, or nontumefactive
inflammatory CNS disorders, with 96% sensitivity and 93%
specificity for the diagnosis of PCNSL.
5.1. Take Home Message. Combined “classical” CSF analysis
(i.e., CM and CFM) increases the diagnostic accuracy for
PCNSL, but a role for CSF markers of B lymphoid cell prolif-
eration is emerging.These new biomarkers could improve the
differential diagnosis of PCNSL but need to be validated and
standardized before a routine application in clinical practice
takes place.
6. PCNSL Diagnosis: Role of
Ocular Examinations
When PCNSL is suspected, ocular evaluation including
fundoscopy and slit lamp examination should be performed.
Ocular involvement must be confirmed by vitreous biopsy,
and a positive result in a context of brain MRI suspicious
for PCNSL can be diagnostic and avoid brain biopsy. A
positive cytology is obtained in 50% of cases; as for CSF,
immunophenotyping and detection of IgH or T-cell receptor
rearrangements by PCR analysis indicating monoclonality
are helpful tools for diagnosis. Moreover, high levels of IL-
10 and/or high IL-10/IL6 ratio in ocular fluids are strongly
suggestive of B-cell lymphomatous uveitis [9]. Fluorescein
angiography may be useful for lymphomatous involvement
of the retina.
6.1. TakeHomeMessage. Acytological confirmation of ocular
involvement should be performed whenever feasible.
7. PCNSL Diagnosis: Role of Baseline
Cognitive Assessment
Cognitive symptoms are critical domains to assess in PCNSL
patients, since they can prevail at diagnosis. Neuropsycho-
logical baseline testing is fundamental to allow a better
8 BioMed Research International
(a) (b) (c)
Figure 4: Axial 18F-FDG brain imaging. PCNSL (a), glioblastoma multiforme (b), and abscess (c).
interpretation of cognitive decline following therapy and in
follow-up phases. Guidelines from Correa et al. [91] outlined
the importance of standardization of neuropsychological
evaluation in PCNSL: a battery of tests to assess attention,
executive function, verbalmemory,motor function (domains
frequently impaired in PCNSL patients), quality of life, and
premorbid IQ was proposed.
Cognitive assessment may sometimes help in distin-
guishing PCNSL from other nonneoplastic diseases (e.g.,
Creutzfeldt-Jakob disease, autoimmune encephalitis, parane-
oplastic encephalitis, and infectious conditions): in PCNSL
patients, memory impairment is more marked than in other
rapidly progressive dementias (RPDs), while neurological
signs, such as myoclonus and parkinsonism, are very rare
[92].
7.1. TakeHomeMessage. Cognitive tests should be performed
in PCNSL patients before any antineoplastic therapy.
8. PCNSL Prognostication: Role of
MRI and PET
Recent studies suggest that some parameters of advanced
MRI can predict patients’ prognosis and tumor responsive-
ness to methotrexate-based chemotherapy. Zhang et al. [93]
investigatedADCas a prognostic indicator in 28 patientswith
PCNSL receiving high-dose methotrexate-based chemother-
apy: patients with higher ADC 5% (ADC at 5% percentile)
showed significantly longer progression-free survival (PFS).
Similarly, Barajas et al. [94] showed an inverse correlation
between cellular density and ADC measurement: in partic-
ular, ADC 25% values (ADC at 25% percentile) less than
the median value of 692 (“low ADC group”) were associated
with significantly shorter progression-free survival (PFS) and
overall survival (OS).
Wieduwilt et al. [95] reported similar results, demon-
strating shorter PFS and OS in patients with lower ADCmin
values (less than 384 X10−6) prior to immunochemotherapy.
Valles et al. [96] reported that PCNSL patients with low
ADCmin or low rCBV values have worse PFS and OS
and hypothesized that low tumor rCBV in PCNSL could
express a lack of tumor angiogenesis and a decrease in the
number of vessels able to deliver intravenous methotrexate
to the tumor. In line with these findings, Chung et al. [97]
showed that the pattern of DCE-MRI could be a marker for
predicting complete response (CR) and longer PFS following
chemotherapy, with a strong association between “diffuse”
DCE-MRI pattern and CR. Regarding 18F-FDG-PET, Kawai
et al. [98] demonstrated that pretreatment 18F-FDG uptake
can predict survival in PCNSL patients: the median survival
time of patients with low-to-moderate 18F-FDG uptake
(SUVmax < 12) was significantly longer (26 months) than
that of patients with high 18F-FDG uptake (SUVmax ≥ 12; 12
months).
8.1. Take Home Message. Prognostication by MRI and PET
is thus far limited to clinical trials. Nonetheless, a correlation
between lower ADC (reflecting high tumor cellularity), lower
rCBV (reflecting poor vascularity), higher FDGmetabolism,
and relatively poorer response to treatment can be hypothe-
sized.
9. PCNSL Prognostication: Role of CSF
CSF IL-10 levels decrease after PCNSL treatment [86, 87]
and increase at time of relapse [86]. High baseline and
posttreatment IL-10 levels have been associated with poor
PFS [86–88].Moreover, CSFOPN levels have been associated
with shorter PFS and OS [89]. Other potential biomarkers
of PCNSL, related to disease response to therapy, include
CSF levels of transmembrane activator and CAML inter-
actor (TACI), soluble CD19 [99], antithrombin III [100],
free immunoglobulin light chains [101], CXCL13 [102], and
miRNAs. With regard to the latter, Baraniskin et al. [103]
demonstrated the ability of CSF miR-21, miR-19b, and miR-
92 levels to differentiate PCNSL from other nonneoplastic
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neurological disorders and correlate with different phases of
PCNSL disease. No role was demonstrated for serummiRNA
levels.
9.1. Take Home Messages. Prognostication by CSF markers is
thus far limited to clinical trials.
10. PCNSL Treatment:
Monitoring of the Disease
Standard treatment of PCNSL includes 2 phases: induction
and consolidation. Induction strategies usually consist in
high-dosemethotrexate- (HD-MTX-) based polychemother-
apy: combination of HD-MTX with other CT agents could
improve response compared with HD-MTX alone. Drugs
found to be useful and safe when combined with HD-
MTX are cytarabine, lomustine, procarbazine, vinca alka-
loids, temozolomide, and thiotepa [104]. HD-MTX-based
polychemotherapy can be associated with the administration
of rituximab (RTX), an anti-CD-20 monoclonal antibody
[4, 105].
Induction phase is followed by consolidation treat-
ments, such as whole-brain radiotherapy (WBRT), high-dose
myeloablative chemotherapy supported by autologous stem-
cell transplantation (HDC-ASCT), and nonmyeloablative
chemotherapy. WBRT was for long time used with doses
between 40 and 45Gy in 20–25 fractions, but these doseswere
associated with important cognitive dysfunctions: for this
reason, reduced-dose (RD) WBRT (23.4Gy) is commonly
used. A recent phase III study by Thiel et al. [106] suggested
that consolidation with RD-WBRT can improve patients’
PFS but not OS. On these bases and considering the risk
of neurotoxicity related to RT, consolidation strategies to
minimize neurotoxicity have been proposed, such as avoiding
WBRT in patientswithCR after chemotherapy, lower doses of
WBRT, and replacing consolidation radiotherapy with other
treatments such as ASCT [107, 108].
A recent International Extranodal Lymphoma Study
Group-32 (IELSG32) trial proposed the regimen MATRix (a
combination of HD-MTX, HD-ARAC [cytarabine] thiotepa,
and rituximab) as new standard chemoimmunotherapy [109].
Treatment regimens based on CT (i.e., HD-MTX alone
or associated with other chemotherapeutic agents such as
temozolomide) have been suggested as a reasonable approach
for elderly patients with good PS and renal function [110–112].
Patients with recurrent/refractory disease typically have
poor outcomes, with response rates ranging between 30 and
60% and PFS ranging between 2 and 6 months. The key
points in relapsed disease are MTX sensitivity and perfor-
mance status of the patient. In cases with MTX-sensitive
relapse, additional MTX cycles must be administered to
achieve maximal cytoreduction (6–8 cycles). This must be
followed by dose-intensive CT consolidation in “fit patients,”
CNS penetrant agents such as thiotepa, or carmustine-
based regimens. Topotecan, temozolomide, pemetrexed,
bendamustine, PCV, ifosfamide-etoposide-based regimen,
and cisplatin-cytarabine-based regimens are feasible choices
for salvage treatment. However, a standard of care thus does
not exist so far. The most appropriate salvage treatment
should be chosen on the basis of patient’s age, PS, comor-
bidities, site of relapse, previous therapy, and duration of
previous response and expected side effects of salvage drugs.
HDCTwithASCT is an option in selected relapsed/refractory
cases, but there is evidence of superiority of this strategy to
chemoradiotherapy [4].
New targeted agents, such as lenalidomide and ibrutinib,
are showing preliminary interesting results in relapsed CNS
lymphoma [113, 114]. Other promising therapeutic agents are
the “check-point inhibitors” of PD-1/PD-L1 pathway, which
play a crucial role in tumor immunology [115]. PD-1/PD-
L1 expression has been recently detected in 42% of the
lymphomas in a large cohort of 10.187 PCNSL samples [116].
11. MRI and PET: What to Value and When
The International Primary CNS Lymphoma Collaborative
Group defined in 2005 the guidelines for evaluating PCNSL
response to treatments based on the evaluation of gadolin-
ium enhancement on MRI, use of corticosteroids, eye
examination, and CSF cytology. Combining these elements,
patients’ response to therapy can be defined as complete
response (CR), unconfirmed complete response (uCR), par-
tial response (PR), stable disease (SD), or progressive disease
(PD) [117].
Patients enrolled into clinical trials should be assessed
after the completion of therapy by brain imaging at a
minimum of 3 months for 2 years and then every 6 months
for 3 years and yearly for at least 5 years. A recent study
by Fossard et al. [118] aimed to define the best follow-up
strategy for PCNSL patients after first-line therapy in clinical
practice. 125 PCNSL patients, who achieved CR after first-
line therapy, started the follow-up and the timing of planned
visits and MRI was defined by each center. Overall, serial
imaging detected relapses in a minority of asymptomatic
patients only. No differences in patient outcome between
symptomatic and asymptomatic relapses were seen. Tabouret
et al. [119] investigated the prognostic value of conventional
MRI characteristic and defined tumor responsiveness to
chemotherapy. In a cohort of 85 PCNSLs, infratentorial
location was associated with shorter OS and larger enhancing
tumor volume correlated with poor PFS; moreover, the
percentage of decrease in T1 enhancement between baseline
and first MRI evaluation correlated with OS. These authors
also described at baseline T2-FLAIR hyperintense lesions
distant from the enhancing tumor in 26% of patients: 89%
of these lesions decreased after chemotherapy, and in 50% of
patients relapses originated from these areas, reinforcing the
hypothesis of their neoplastic nature. These data underline
the difficulty of interpretation, especially after treatment,
of T2-FLAIR hyperintense nonenhancing alterations, which
can be variably attributed to vascular damage, leukoen-
cephalopathy related to MTX or radiotherapy, or neoplastic
tissue.
Advanced MRI techniques and FDG-PET or MET-PET
could improve the prediction of response, progression, and
outcome. A reduction of ADC values after chemotherapy
10 BioMed Research International
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correlatedwithmethotrexate responsiveness [93]. Palmedo et
al. [120] showed that FDG-PET was able to predict complete
remission or tumor recurrence after chemotherapy in 8
patients affected by PCNSL. Jo et al. [121] showed that patients
with negative FDG-PET after chemotherapy had significantly
longer progression-free survival, but not overall survival,
compared to the group with positive posttreatment PET.
Conversely, Mercadal et al. [122] detected a difference in
overall survival between negative and positive posttreatment
FDG-PET patients (100% versus 37.5%, resp., 𝑝 = 0.045).
Some authors have hypothized that the reduction of 18F-
FDG uptake after the first cycles of chemotherapy could
precede the reduction of tumor size on MRI [98]. Thus, the
combination of 18F-FDG-PET and MRI could improve the
evaluation of treatment response [123] and the appreciation
of residualMRI lesions during follow-up examinations. [122].
MET-PET could be useful for an early delineation of response
to systemic chemotherapy or radiotherapy [124].
In conclusion, FDG-PET can be used to evaluate treat-
ment response of PCNSL at a very early stage and predict a
more aggressive disease course. During long-term follow-up,
FDG-PET findings could anticipate the diagnosis of PCNSL
recurrence, even if this hypothesis should be demonstrated
in prospective studies with higher number of patients. MET-
PET may have a role in identifying residual tumor that is
difficult to detect by MRI owing to the effects of previous
radiotherapy or surgery [Table 1].
11.1. Take Home Message. In the daily clinical practice,
monitoring of response/progression with enhanced MRI
is mandatory, while advanced MRI techniques and PET
imaging are confined to clinical trials.
12. Cognitive Monitoring
Serial monitoring of cognitive functions is important for
two reasons. First, cognitive impairment can be a marker of
recurrence. Fossard et al. [118] reported that 80% of PCNSL
relapses were not detected by MRI examinations but on
the basis of neurological symptoms, in particular cognitive
impairment in 43% of patients. Second, cognitive follow-
up is crucial to assess the long-term effects of treatments,
in particular central neurotoxicity. Clinically, neurotoxicity
presents as a progressive cognitive impairment, which can
lead to dementia, and develops after a variable delay from
the end of treatment. Cognitive dysfunctions can parallel
or follow motor and autonomic symptoms. Clinical features
mimic diseases, such as Binswanger dementia or normal
pressure hydrocephalus [125]. Risk factors for neurotoxi-
city include older age, comorbidities, leptomeningeal dis-
ease, WBRT, and aggressive chemotherapy regimens. Several
chemotherapeutic agents, particularly HD-MTX and high-
dose cytarabine, have been shown to cause periventricu-
lar white matter abnormalities [126]. Combined regimens,
includingWBRT, display a higher percentage of neurotoxicity
when compared to chemotherapy alone, with an incidence of
neurotoxicity ranging from 8% to 50% of patients [126–132].
Combined modality treatments, including RT, are associated
with cognitive impairment even in patients below 60 years
of age [133], but the frequency is higher above 60 years of
age. For this reason, many authors suggest to defer WBRT at
recurrence in older patients [134–136]. Encouraging results
are coming from trials on HDC-ASCT, with no significant
neurotoxicity and even improved cognitive functions and/or
quality of life [108, 125].
The possibility to derive information on treatments
neurotoxicity depends on cognitive testing of patients in
remission, since in cases of PCNSL progression the cognitive
decline depends on the disease itself [91].
12.1. Take Home Message. In daily clinical practice, cognitive
testing should be encouraged to better define the cognitive
profile in the different scenarios (persistent response versus
disease recurrence).
13. Conclusions
The knowledge of neuroimaging and biological markers
of PCNSL is rapidly growing. Thus, it is conceivable that
in future years the scenario of PCNSL management will
change, moving to a better disease-profiling and “tailored-
on-patient” therapies. Cooperation and scientific dialogue
between different medical professionals (neurologists, neu-
roradiologists, nuclear medicine physicians, hematologists,
oncologists, neurosurgeons, ophthalmologists, pathologists,
and psychologists) are essential to improve diagnosis, prog-
nosis, treatment strategies, and outcomes of such a complex
disease in both clinical trials and everyday clinical activity.
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